

Francois Habersetzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11435571/publications.pdf>

Version: 2024-02-01

38
papers

3,294
citations

430442

18
h-index

329751

37
g-index

38
all docs

38
docs citations

38
times ranked

5428
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 677-689.	1.5	6
2	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. <i>BMC Infectious Diseases</i> , 2022, 22, 94.	1.3	6
3	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. <i>JHEP Reports</i> , 2022, 4, 100481.	2.6	3
4	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. <i>Journal of Cannabis Research</i> , 2022, 4, .	1.5	1
5	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. <i>Clinical Therapeutics</i> , 2021, 43, 1201-1212.	1.1	4
6	Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). <i>European Journal of Cancer</i> , 2021, 154, 46-56.	1.3	10
7	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101713.	0.7	10
8	Upper gastrointestinal bleeding due to left side portal hypertension after pancreatic surgery. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, , .	0.6	0
9	Safe administration of corticosteroids in severe ulcerative colitis and active SARS-CoV2 infection. <i>Digestive and Liver Disease</i> , 2020, 52, 1257-1258.	0.4	1
10	Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection. <i>Hepatology</i> , 2019, 70, 1506-1520.	3.6	21
11	Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference. <i>Journal of Hepatology</i> , 2019, 70, 1297-1300.	1.8	2
12	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	3.7	36
13	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. <i>Lancet, The</i> , 2019, 393, 1453-1464.	6.3	449
14	12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. <i>Hepatology</i> , 2018, 68, 1277-1287.	3.6	11
15	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2018, 378, 2171-2181.	13.9	383
16	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1624-1636.	5.1	595
17	Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. <i>American Journal of Transplantation</i> , 2017, 17, 2869-2878.	2.6	6
18	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017, 66, 39-47.	1.8	100

#	ARTICLE	IF	CITATIONS
19	Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin. <i>Hepatology</i> , 2016, 64, 1495-1506.	3.6	8
20	Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – The ANRS CUIPILT study. <i>Journal of Hepatology</i> , 2016, 65, 711-718.	1.8	72
21	A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. <i>Hepatology</i> , 2016, 63, 35-48.	3.6	131
22	Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies. <i>Gastroenterology</i> , 2016, 150, 206-217.e4.	0.6	64
23	Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties. <i>Hepatology</i> , 2015, 62, 726-736.	3.6	4
24	Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. <i>Hepatology</i> , 2015, 61, 1485-1494.	3.6	206
25	Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. <i>Gut</i> , 2015, 64, 483-494.	6.1	83
26	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). <i>Lancet Infectious Diseases</i> , The, 2015, 15, 397-404.	4.6	267
27	Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection. <i>Liver International</i> , 2015, 35, 130-139.	1.9	29
28	Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents. <i>PLoS Pathogens</i> , 2014, 10, e1004128.	2.1	97
29	All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. <i>Hepatology</i> , 2014, 60, 56-64.	3.6	43
30	Interferon-Induced Protein 10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response. <i>Journal of Infectious Diseases</i> , 2014, 210, 1881-1885.	1.9	19
31	Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13109-13113.	3.3	422
32	Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization. <i>Journal of Infectious Diseases</i> , 2013, 207, 1306-1315.	1.9	9
33	Hepatitis C virus vaccines – Progress and perspectives. <i>Microbial Pathogenesis</i> , 2013, 58, 66-72.	1.3	34
34	Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 853-862.	1.9	1
35	Genotype 1 Hepatitis C Virus Envelope Features That Determine Antiviral Response Assessed through Optimal Covariance Networks. <i>PLoS ONE</i> , 2013, 8, e67254.	1.1	8
36	Challenges for HCV vaccine development in HIV-HCV coinfection. <i>Expert Review of Vaccines</i> , 2012, 11, 791-804.	2.0	8

#	ARTICLE	IF	CITATIONS
37	Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies. <i>Gastroenterology</i> , 2012, 143, 223-233.e9.	0.6	66
38	A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 141, 890-899.e4.	0.6	79